Understanding Disparities in AD
Understanding Disparities in AD
DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
New Drugs Helping AD Catch Up to Psoriasis
New Drugs Helping AD Catch Up to Psoriasis
Addressing the Unique Challenges of AD Patients
Addressing the Unique Challenges of AD Patients
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
Itching for More: Treatment Options Continue to Expand for Itch and Pain
Itching for More: Treatment Options Continue to Expand for Itch and Pain
ISDPA: Dr. Bhatia on JAK Inhibitors
ISDPA: Dr. Bhatia on JAK Inhibitors
ISDPA: Dr. Bhatia and Dr. Zirwas Discuss the Itchy Patient
ISDPA: Dr. Bhatia and Dr. Zirwas Discuss the Itchy Patient
Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
Pearls for Monitoring and Managing Itch: An Expert Panel
Pearls for Monitoring and Managing Itch: An Expert Panel
Talking to Patients About Starting a JAK Inhibitor in Atopic Dermatitis
Talking to Patients About Starting a JAK Inhibitor in Atopic Dermatitis
Upadacitinib Therapy in a Pediatric Patient with Infliximab-Induced Skin Eruption
Upadacitinib Therapy in a Pediatric Patient with Infliximab-Induced Skin Eruption
DERM2024: Dr. Friedman on Atopic Dermatitis Diagnosis
DERM2024: Dr. Friedman on Atopic Dermatitis Diagnosis
